ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-5166ometendo-5166Research ArticleСтатьиArticlesСравнение эффективности моксонидина и метопрололау пациентов с артериальной гипертонией и сахарнымдиабетом 2 типа (влияние на артериальное давлениеи метаболические параметры)Sravnenie effektivnosti moksonidina i metoprololau patsientov s arterial'noy gipertoniey i sakharnymdiabetom 2 tipa (vliyanie na arterial'noe davleniei metabolicheskie parametry)---20071506200742№2 (2007)3839Copyright © - -., 20072007- -.- -.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/5166ReferencesS. Jacob, H.-J. Klimm, K. Rett, K. Helsberg, H.-U. Haring, J. Godicke.Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes.S. Jacob, H.-J. Klimm, K. Rett, K. Helsberg, H.-U. Haring, J. Godicke.Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes.Ernsberger P., Ishizuka T., Liu S., Farrell C.J., Bedol D., Koletsky R.J., Friedman J.E. Mechanism of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). J Pharmacol Exp Ther. 1999;288:139-47.Ernsberger P., Ishizuka T., Liu S., Farrell C.J., Bedol D., Koletsky R.J., Friedman J.E. Mechanism of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). J Pharmacol Exp Ther. 1999;288:139-47.Ferrannini E., Buzzigoli G., Bonadonna R., Giorico M.A., Oleggini M., Graziadei L, Pedrinelli R., Brandi L., Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-7.Ferrannini E., Buzzigoli G., Bonadonna R., Giorico M.A., Oleggini M., Graziadei L, Pedrinelli R., Brandi L., Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-7.Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34.Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34.Haenni A., Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens. 1999;17(Suppl 3):29-35.Haenni A., Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens. 1999;17(Suppl 3):29-35.Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A., Luomanmaki K., Dahlöf B., de Faire U., Morlin C., Karlberg B.E., Wester P.O., Bjorck J.E. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-6.Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A., Luomanmaki K., Dahlöf B., de Faire U., Morlin C., Karlberg B.E., Wester P.O., Bjorck J.E. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension:the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-6.Lindholm L.H., Ibsen H., Dahlöf B., Devereux R.B., Beevers G., de Faire U., Fehrquist F., Julius S., Kjeldsen S.E., Kristiansson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J., Snapinn S. The LIFE Study Group. Cardiovascular morbidity and mortality in subjects with type 2 diabetes with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-10.Lindholm L.H., Ibsen H., Dahlöf B., Devereux R.B., Beevers G., de Faire U., Fehrquist F., Julius S., Kjeldsen S.E., Kristiansson K., Lederballe-Pedersen O., Nieminen M.S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J., Snapinn S. The LIFE Study Group. Cardiovascular morbidity and mortality in subjects with type 2 diabetes with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-10.UKPDS 39. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UK Prospective Diabetes Study Group. BMJ. 1998;317:713-20.UKPDS 39. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UK Prospective Diabetes Study Group. BMJ. 1998;317:713-20.
The authors declare that there are no conflicts of interest present.